FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3148870912> ?p ?o ?g. }

• W3148870912 endingPage "104" @default.
• W3148870912 startingPage "89" @default.
• W3148870912 abstract "Abstract This work is a continuation of an earlier article published in this journal (no. 91/1: “Current aspects of polycystic ovary syndrome I: definition, pathophysiology, clinical manifestations, diagnosis and complications”). As the pathology of polycystic ovary syndrome is not fully known, the treatments used do not constitute a causal therapy, only pathogenetical interventions to break the vicious circles of pathological events. It does not currently have a universal therapeutic procedure or an approved specific drug. Treatment may be aimed at reducing hyperandrogenism, inducing ovulation and preventing complications. The patient’s complaints and desire for becoming pregnant should also be taken into account. In mild cases, an appropriate lifestyle (prevention/treatment of obesity) is sufficient, i.e. a 5-10% reduction in body weight can already result in significant improvement and also serves to prevent late complications (diabetes, hypertension, cardiovascular disease, hyperlipidemia). Oral contraceptives and antiandrogens are mainly used to treat hyperandrogenism (hirsutism, acne, and alopecia). A contraceptive whose progestogen component has antiandrogenic properties, or at least is androgen-neutral, is preferred, such as third-generation contraceptives. However, combined contraceptives (containing gestodene, desogestrel, drospirenone and cyproterone acetate) may increase the risk of venous thromboembolism and are therefore contraindicated in case of hypercoagulability. Antiandrogens (cyproterone acetate, spironolactone, finasteride, etc.) can also be used independently, but only with effective contraception (as these can cause feminization of the male fetus). Insulin resistance plays a crucial role in the development of this disease. Metformin is used as primary therapy, as it also has many other beneficial effects (e.g. cardiovascular and anti-cancer) described in recent years. These pleiotropic effects and their subtle mechanisms are discussed in detail. We highlight the possibilities of avoiding side effects and the current interpretation of rare contraindications (acidosis, hypoxic conditions, renal damage). Insulin resistance lowering agents include thiazolidinediones, acarbose, GLP-1 agonists, vitamin D, resveratrol, octreotide, but the beneficial effects of myoinositol and D-chiro-inositol are also mentioned. In the last part of the paper, the treatment options for infertility are discussed, highlighting the efficacy of clomiphene citrate, gonadotropins (“step-up”, “step- down” methods), IVF techniques, and ovarian drilling used for ovulation induction. We detail the importance and possibilities of the prevention of ovarian hyperstimulation syndrome and multiple pregnancies." @default.
• W3148870912 created "2021-04-13" @default.
• W3148870912 creator A5037232395 @default.
• W3148870912 date "2019-12-01" @default.
• W3148870912 modified "2023-09-27" @default.
• W3148870912 title "Current aspects of polycystic ovary syndrome II: treatment of hyperandrogenism, insulin resistance and infertility" @default.
• W3148870912 cites W1864860694 @default.
• W3148870912 cites W1963543729 @default.
• W3148870912 cites W1963738625 @default.
• W3148870912 cites W1984067141 @default.
• W3148870912 cites W1993252966 @default.
• W3148870912 cites W1999822214 @default.
• W3148870912 cites W2000396770 @default.
• W3148870912 cites W2020816546 @default.
• W3148870912 cites W2023332915 @default.
• W3148870912 cites W2031635887 @default.
• W3148870912 cites W2033846469 @default.
• W3148870912 cites W2037699368 @default.
• W3148870912 cites W2066032552 @default.
• W3148870912 cites W2073427932 @default.
• W3148870912 cites W2078318839 @default.
• W3148870912 cites W2090383344 @default.
• W3148870912 cites W2101802759 @default.
• W3148870912 cites W2109580294 @default.
• W3148870912 cites W2118710260 @default.
• W3148870912 cites W2120973019 @default.
• W3148870912 cites W2126141712 @default.
• W3148870912 cites W2130974208 @default.
• W3148870912 cites W2141350591 @default.
• W3148870912 cites W2147127250 @default.
• W3148870912 cites W2155715955 @default.
• W3148870912 cites W2161436608 @default.
• W3148870912 cites W2166566949 @default.
• W3148870912 cites W2407202971 @default.
• W3148870912 cites W2481420451 @default.
• W3148870912 cites W2491649426 @default.
• W3148870912 cites W2520838590 @default.
• W3148870912 cites W2525729089 @default.
• W3148870912 cites W2532986090 @default.
• W3148870912 cites W2570191103 @default.
• W3148870912 cites W2575406652 @default.
• W3148870912 cites W2587682809 @default.
• W3148870912 cites W2592172277 @default.
• W3148870912 cites W2609651499 @default.
• W3148870912 cites W2619367813 @default.
• W3148870912 cites W2739112346 @default.
• W3148870912 cites W2751479028 @default.
• W3148870912 cites W2777731218 @default.
• W3148870912 cites W2783974072 @default.
• W3148870912 cites W2788018146 @default.
• W3148870912 cites W2790276328 @default.
• W3148870912 cites W2792000617 @default.
• W3148870912 cites W2793887346 @default.
• W3148870912 cites W2810832714 @default.
• W3148870912 cites W2885509473 @default.
• W3148870912 cites W4229513803 @default.
• W3148870912 doi "https://doi.org/10.2478/orvtudert-2019-0016" @default.
• W3148870912 hasPublicationYear "2019" @default.
• W3148870912 type Work @default.
• W3148870912 sameAs 3148870912 @default.
• W3148870912 citedByCount "0" @default.
• W3148870912 crossrefType "journal-article" @default.
• W3148870912 hasAuthorship W3148870912A5037232395 @default.
• W3148870912 hasBestOaLocation W31488709121 @default.
• W3148870912 hasConcept C126322002 @default.
• W3148870912 hasConcept C134018914 @default.
• W3148870912 hasConcept C2776306840 @default.
• W3148870912 hasConcept C2776371013 @default.
• W3148870912 hasConcept C2776379505 @default.
• W3148870912 hasConcept C2777155358 @default.
• W3148870912 hasConcept C2777391703 @default.
• W3148870912 hasConcept C2777911890 @default.
• W3148870912 hasConcept C2778198053 @default.
• W3148870912 hasConcept C2779076696 @default.
• W3148870912 hasConcept C2779441745 @default.
• W3148870912 hasConcept C2780186808 @default.
• W3148870912 hasConcept C2780853582 @default.
• W3148870912 hasConcept C2908647359 @default.
• W3148870912 hasConcept C29456083 @default.
• W3148870912 hasConcept C2986817661 @default.
• W3148870912 hasConcept C3018442814 @default.
• W3148870912 hasConcept C555293320 @default.
• W3148870912 hasConcept C71315377 @default.
• W3148870912 hasConcept C71924100 @default.
• W3148870912 hasConcept C99454951 @default.
• W3148870912 hasConceptScore W3148870912C126322002 @default.
• W3148870912 hasConceptScore W3148870912C134018914 @default.
• W3148870912 hasConceptScore W3148870912C2776306840 @default.
• W3148870912 hasConceptScore W3148870912C2776371013 @default.
• W3148870912 hasConceptScore W3148870912C2776379505 @default.
• W3148870912 hasConceptScore W3148870912C2777155358 @default.
• W3148870912 hasConceptScore W3148870912C2777391703 @default.
• W3148870912 hasConceptScore W3148870912C2777911890 @default.
• W3148870912 hasConceptScore W3148870912C2778198053 @default.
• W3148870912 hasConceptScore W3148870912C2779076696 @default.
• W3148870912 hasConceptScore W3148870912C2779441745 @default.
• W3148870912 hasConceptScore W3148870912C2780186808 @default.
• W3148870912 hasConceptScore W3148870912C2780853582 @default.

• next